Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Year Established: | 2006 |
Funding: | 25 |
Address: | San Francisco, CA 94104 |
Telephone: | |
Mobile: | |
Fax: | |
Mail: | SARcode@sarcode.com |
Company URL: | http://www.sarcode.com |
SAN FRANCISCO Calif. January 15 2010 ââ¬â SARcode Corporation a privately held biopharmaceutical company focused on developing small molecule leukocyte function-associated antigen-1 (LFA-1) inhibitors to treat inflammator diseases today announced the completion of enrollment of its Phase 2 study of topically administered SAR 1118 Ophthalmic Solution in subjects with dry eye disease (keratoconjunctivitis sicca KCS). The study is fully enrolled with 230 subjects. Study completion is anticipated in February 2010 with top-line data available at the end of Q1 2010.
Download PDF of Complete January 15th News Release
SAN FRANCISCO March 30 2009 ââ¬â SARcode Corporation announced today the results of its Phase 1 randomized double-masked placebo-controlled trial of the safety tolerability and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.Ã
Alta Partners,Clarus Ventures,Undisclosed Firm
John Burnier, PhD, President
Charles Semba, MD, Chief Medical Officer
Mary Newman, MS, Vice President - Regulatory Affairs
Valerie Smith, MBA, Senior Director - Clinical Operations